Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?

Objective. To compare health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA) to that of the general population and to investigate the association with disease activity, focusing on different clinical remission criteria. Methods. EQ-5D data from 3156 patients with RA from 11 Danish centers were compared with Danish EQ-5D population norms (n = 16,136). The Disease Activity Score (DAS28) and the Clinical Disease Activity Index score (CDAI) were used as definitions of disease activity and clinical remission. The score difference (ΔEQ-5D) was calculated in each patient as the difference from the age and sex-matched general population and adjusted for age, marital status, education, body mass index, smoking, exercise habits, disease duration, IgM-rheumatoid factor status, joint surgery, extraarticular features, treatment, and comorbidity in multiple linear regression models. Results. 37% vs 22% fulfilled the DAS28 and CDAI remission criteria, respectively. The ΔEQ-5D values for women/men in clinical remission were DAS28 0.05/0.06 vs CDAI 0.01/0.02; low disease activity: DAS28 0.12/0.13 vs CDAI 0.11/0.14; moderate disease activity: DAS28 0.18/0.20 vs CDAI 0.20/0.23; and high disease activity: DAS28 0.38/0.28 vs CDAI 0.33/0.26. Adjusting for confounders reduced the ΔEQ-5D values between 0 and 0.04 units. Conclusion. Patients with RA had worse EQ-5D scores than the general population, and the difference was strongly associated with disease activity. The EQ-5D score for patients in clinical remission approached that of the general population, suggesting that strict treatment goals are critical in order to achieve near-normal HRQOL in patients with RA.

[1]  C. Gudex,et al.  Danish EQ-5D population norms , 2009, Scandinavian journal of public health.

[2]  C. Gudex,et al.  Generation of a Danish TTO value set for EQ-5D health states , 2009, Scandinavian journal of public health.

[3]  C. Peterfy,et al.  An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[4]  T. Pincus,et al.  Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. , 2008, Arthritis and rheumatism.

[5]  F. Wolfe,et al.  The problem of rheumatoid arthritis disease activity and remission in clinical practice. , 2008, The Journal of rheumatology.

[6]  G. Reed,et al.  Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care? , 2008, Clinical and experimental rheumatology.

[7]  H. Sintonen,et al.  Health-related quality of life in patients with common rheumatic diseases referred to a university clinic , 2008, Rheumatology International.

[8]  J. Loge,et al.  Health-related quality of life in women with symptomatic hand osteoarthritis: a comparison with rheumatoid arthritis patients, healthy controls, and normative data. , 2007, Arthritis and rheumatism.

[9]  F. Wolfe,et al.  Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[10]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[11]  J. Loge,et al.  Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. , 2007, The Journal of rheumatology.

[12]  Mark Oppe,et al.  EQ-5D value sets : inventory, comparative review, and user guide , 2007 .

[13]  H. Mäkinen,et al.  Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. , 2006, Clinical and experimental rheumatology.

[14]  M. Hetland,et al.  DANBIO: a nationwide registry of biological therapies in Denmark. , 2005, Clinical and experimental rheumatology.

[15]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[16]  Jacek A Kopec,et al.  A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. , 2005, Social science & medicine.

[17]  Paul Kind,et al.  EQ-5D concepts and methods : a developmental history , 2005 .

[18]  H. Picavet,et al.  Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study , 2004, Annals of the rheumatic diseases.

[19]  Maarten Boers,et al.  Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.

[20]  E. Perfetto,et al.  Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. , 2002, The American journal of managed care.

[21]  P. Kind,et al.  Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). , 1997, British journal of rheumatology.

[22]  B. Bresnihan,et al.  Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. , 1996, British journal of rheumatology.

[23]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .